Kaija Halonen

Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial

Eeva‐Marja Rutanen, Jorma Heikkinen, Kaija Halonen et al. · Menopause The Journal of The North American Menopause Society · 2003 · 106 citations

Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

Janne Komi, Kari S. Lankinen, Michael W. DeGregorio et al. · Journal of Bone and Mineral Metabolism · 2006 · 76 citations

Bone Disease, Biochemical Markers, Bone Health +10

Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women

Olavi Ylikorkala, Bruno Cacciatore, Kaija Halonen et al. · Menopause The Journal of The North American Menopause Society · 2003 · 45 citations

Hormonal effects of MPV‐2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study

Outi Ahokoski, Kerttu Irjala, Risto Huupponen et al. · British Journal of Clinical Pharmacology · 1998 · 18 citations · Full text

Pharmacokinetics of finrozole (MPV‐2213ad), a novel selective aromatase inhibitor, in healthy men

Outi Ahokoski, Kerttu Irjala, Mikko Taalikka et al. · British Journal of Clinical Pharmacology · 2001 · 10 citations · Full text